

CD40

Research Grade Sotigalimab

Catalog No.	DHD68911A DHD68911B	Quantity:	100 µg 1.0 mg
Alternate Names:	APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6		
Description:	Research Grade Sotigalimab is a humanized monoclonal antibody directed against human Tumor necrosis factor receptor superfamily member 5 (CD40, Bp50). A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.		
UniProt ID (target):	P25942		
Target:	Human Tumor necrosis factor receptor superfamily member 5 (CD40, Bp50)		
Concentration:	1.0 mg/ml, lot specific		
Source:	Mammalian cells		
Isotype:	Human IgG1 kappa		
Formulation:	Sterile-filtered 0.01 M PBS, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography from cell culture supernatant		
INN:	Sotigalimab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences[®]
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com